国际麻醉学与复苏杂志   2021, Issue (12): 4-4
    
右美托咪定用于丙泊酚麻醉下改良电休克治疗的研究进展
王婷仙, 吕洁萍1()
1.山西医科大学麻醉学院
Research advances of dexmedetomidine in modified electroconvulsive therapy under propofol anesthesia
 全文:
摘要:

改良电休克治疗(modified electroconvulsive therapy, MECT)是目前临床上用于治疗严重精神疾病的有效物理方法。右美托咪定(dexmedetomidine, Dex)是一种亲脂性的α羟甲基衍生物,具有镇静、止痛和阻滞交感神经的作用,易于唤醒,利于稳定循环,近年来Dex也开始用于MECT的麻醉。文章就Dex用于常规丙泊酚麻醉下MECT的临床应用进展进行综述,描述MECT手术的麻醉特点以及Dex用于MECT手术麻醉的安全性与临床效果。

关键词: 右美托咪定; 改良电休克治疗; 丙泊酚; 麻醉
Abstract:

Modified electroconvulsive therapy (MECT) is currently an effective method for the treatment of severe mental disorders. Dexmetomidine (Dex) is a lipophilic α⁃hydroxymethyl derivative which is effective on sedation, analgesia and sympathetic nerve block. The patients who receive Dex are easy to be waken up and maintain stable circulation so that Dex has also been used in MECT surgery recently. This review summarizes the clinical application of Dex in modified electroconvulsive therapy under conventional propofol anesthesia. This review describes the surgical anesthesia characteristics of MECT, the safety and clinical effects of Dex on MECT anesthesia.

Key words: Dexmetomidine; Modified electroconvulsive therapy; Propofol; Anesthesia